The investor is betting that blank-check mergers continue to be an attractive alternative to traditional IPOs amid the current market volatility.
A judge finds Bill Ackman can be sued for allegedly buying a stake in Allergan based on inside information about a takeover bid by Valeant Pharmaceuticals.
The takeover contest's outcome becomes unclear when we consider the conflict between the hedge fund’s objectives and the Allergan board's fiduciary duty.
Activist investing meets activist government.
